Artiva Biotherapeutics Announces Data Presentations On Allogenic NK Cell Therapy June 3-6
Benzinga Newsdesk 5 months ago
News
Abstracts:LB0003Oral PresentationAB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with
Abstracts:
| LB0003 Oral Presentation | AB-101, an Outpatient-Administered Allogeneic NK Cell Therapy Combined with Rituximab, Generates Robust Clinical Efficacy Responses Comparable with Autologous CAR T in 31 Patients with Rheumatologic Diseases |
| Presenting Author: | Norman B. Gaylis, M.D., F.A.C.P., M.A.C.R. Rheumatologist, Arthritis & Rheumatic Disease Specialties |
| Session: | Late Breaking Abstracts |
| Date/Time/Location: | Saturday, June 6, 2026 at 12:00 – 1:15 pm BST, Room: N3 |
| OP0129 Oral Presentation | AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab was Highly Effective in Severe Sjögren Disease: Experience in First Patient Treated |
| Presenting Author: | Norman B. Gaylis, M.D., F.A.C.P., M.A.C.R. Rheumatologist, Arthritis & Rheumatic Disease Specialties |
| Session: | Clinical Abstract Sessions: Positive Clinical Trials - a new era in Sjögren's Disease |
| Date/Time/Location: | Wednesday, June 3, 2026 at 4:30 – 5:45 pm BST, Room: N3 |
| POS0355 Poster Tour | AB-101, an Allogeneic NK Cell Therapy, in Combination with Anti-CD20 Monoclonal Antibodies, Consistently Achieves Deep B-cell Depletion Comparable with CAR T Cell Therapies in Patients with Rheumatologic Diseases |
| Presenting Author: | Heather Raymon, Ph.D. SVP, Research & Early Development, Artiva Biotherapeutics |
| Session: | Basic Poster Tours: Another one BITes the CAR-T |
| Date/Time/Location: | Saturday, June 6, 2026 at 10:15 – 11:15 am BST, Room: Poster Tour II |
| POS1177 Poster View | Robust and Durable Clinical Responses Observed Following Treatment with AB-101, an Allogeneic NK Cell Therapy, Combined with Rituximab in Patients with Severe Rheumatoid Arthritis and Inadequate Response to Multiple Prior Targeted Therapies |
| Presenting Author: | Guillermo J. Valenzuela, M.D., F.A.C.R. Medical Director, Integral Rheumatology & Immunology Specialists (IRIS) |
| Session: | Poster View VIII |
| Date/Time/Location: | Saturday, June 6, 2026 at 10:15 – 11:15 am BST, Room: Poster View |
| AB0345 Publication Only | Treatment with an Allogeneic NK Cell Therapy, AB-101, in Combination with Anti-CD20 Antibodies in Immune-mediated Diseases Demonstrates a Favorable Safety Profile and Comparable B-cell Depletion to CD19 CAR T Therapies |
| Subhashis Banerjee, M.D. Chief Medical Officer, Artiva Biotherapeutics |